Payment overview · 2025
General Payments
$412.67
23 reported records · 11 companies
Healthcare provider profile · identity verified
Gabe Scott Robin, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LAFAYETTE, LA · NPI 1255568481
Verified facts
What the public records show
CMS Open Payments records show Gabe Scott Robin, NP received $412.67 in general payments during 2025 across 23 reported records.
Viatris Specialty LLC accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Rybelsus, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $108.69 | 26.3% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.85 | 12.1% | 3 | 2025 |
| Cepheid | Unresolved — no canonical attribution shown | $41.72 | 10.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $38.32 | 9.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $36.88 | 8.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.86 | 8.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.32 | 7.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.35 | 4.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.31 | 4.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.90 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.47 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $412.67 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $108.69 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.85 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $38.32 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $36.88 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.32 | 2 | 2025 |
Source payment records
|
|||||
| GeneXpert Normalized: genexpert |
Device | Cepheid | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 48 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
152 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 333 | 66 |
| Gabapentin | Gabapentin | 271 | 49 |
| Omeprazole | Omeprazole | 263 | 58 |
| Glipizide Er | Glipizide | 230 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 58 |
| Metformin Hcl | Metformin Hcl | 222 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 43 |
| Atorvastatin Calcium | Atorvastatin Calcium | 180 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 39 |
| Clonazepam | Clonazepam | 166 | 22 |
| Synthroid | Levothyroxine Sodium | 152 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 123 | 29 |
| Lisinopril | Lisinopril | 123 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 31 |
| Meloxicam | Meloxicam | 120 | 32 |
| Tramadol Hcl | Tramadol Hcl | 116 | 38 |
| Valsartan | Valsartan | 114 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 19 |
| Potassium Chloride | Potassium Chloride | 102 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 24 |
| Famotidine | Famotidine | 89 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 24 |
| Azelastine Hcl | Azelastine Hcl | 86 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 29 |
| Furosemide | Furosemide | 84 | 28 |
| Prednisone | Prednisone | 84 | 61 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 75 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | suppressed |
| Carvedilol | Carvedilol | 71 | 13 |
| Celecoxib | Celecoxib | 69 | 23 |
| Montelukast Sodium | Montelukast Sodium | 67 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 26 |
| Alprazolam | Alprazolam | 59 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | suppressed |
| Eliquis | Apixaban | 54 | suppressed |
| Mounjaro | Tirzepatide | 54 | 14 |
| Cefdinir | Cefdinir | 53 | 47 |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Finasteride | Finasteride | 51 | suppressed |
| Ozempic | Semaglutide | 51 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 41 |
| Linzess | Linaclotide | 48 | 11 |
| Lorazepam | Lorazepam | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | suppressed |
| Levofloxacin | Levofloxacin | 45 | 40 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | 12 |
| Allopurinol | Allopurinol | 41 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 34 |
| Trazodone Hcl | Trazodone Hcl | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Losartan Potassium | Losartan Potassium | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 29 |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 13 |
| Ondansetron Odt | Ondansetron | 23 | 18 |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Budesonide | Budesonide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 11 |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Fluconazole | Fluconazole | 19 | 16 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 11 |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 13 | 11 |
| Diazepam | Diazepam | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $412.67 · 23 records | Viatris Specialty LLC | AIRSUPRA, Cologuard Collection Kit, GeneXpert, IBSRELA, LINZESS, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, REPATHA, Rybelsus, TRINTELLIX, YUPELRI | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error